


Amendments to the Specification

The following claims replace all prior versions.


1. (currently amended) A compound represented by a formula below or a pharmaceutically acceptable salt thereof:




wherein;

R and R' are independently C₁-C₅ alkyl; ~~or together R and R' form carbocyclic ring having from 3 to 8 carbon atoms;~~

R₁ and R₂ are independently hydrogen or C₁-C₅ alkyl;



L₂ is a divalent linking group selected from: a bond and



where m is 0, 1 or 2, and each R₄₀ is independently hydrogen, C₁-C₅ alkyl, or C₁-C₅ fluoroalkyl;

R₂BOH is

3-methyl-3-hydroxypentyl,
3-methyl-3-hydroxypentenyl,
3-methyl-3-hydroxypentynyl,
3-ethyl-3-hydroxypentyl,
3-ethyl-3-hydroxypentenyl,
3-ethyl-3-hydroxypentynyl,
3-ethyl-3-hydroxy-4-methylpentyl,
3-ethyl-3-hydroxy-4-methylpentenyl,
3-ethyl-3-hydroxy-4-methylpentynyl,
3-propyl-3-hydroxypentyl,
3-propyl-3-hydroxypentenyl,
3-propyl-3-hydroxypentynyl,
1-hydroxy-2-methyl-1-(methylethyl)propyl,
1-hydroxycyclopropyl,
1-hydroxycyclobutyl,
1-hydroxycyclopentyl, or
1-hydroxycyclohexyl;

provided, however, provided that when

R₂BOH is

3-methyl-3-hydroxypentyl,
3-methyl-3-hydroxypentenyl,
3-methyl-3-hydroxypentynyl,
3-ethyl-3-hydroxypentyl,
3-ethyl-3-hydroxypentenyl,
3-ethyl-3-hydroxypentynyl,
3-ethyl-3-hydroxy-4-methylpentyl,
3-ethyl-3-hydroxy-4-methylpentenyl,
3-ethyl-3-hydroxy-4-methylpentynyl,
3-propyl-3-hydroxypentyl,
3-propyl-3-hydroxypentenyl,
3-propyl-3-hydroxypentynyl, or
1-hydroxy-2-methyl-1-(methylethyl)propyl;


then L_1 and L_2 combine as a bond; and

R_C is

-C(O)NH-CH₂-C(O)OH,
 -C(O)NH-CH(Me)-C(O)OH,
 -C(O)NH-C(Me)₂-C(O)OH,
 -C(O)NMe-CH₂-C(O)OH,
 -C(O)NMe-CH(Me)-C(O)OH,
 -C(O)NMe-C(Me)₂-C(O)OH, or
 -5-tetrazolyl;

2. (canceled)

3. (currently amended) A compound represented by formula (II) or a pharmaceutically acceptable salt thereof:



wherein;

R and R' are independently methyl or ethyl;


R_1 and R_2 are independently methyl or ethyl;

L_1 is a divalent linking group selected from: a bond and $-(CH_2)_m-C(=O)-$,

$-(CH_2)_m-O-$, $-(CH_2)_m-CH=CH-$,

$-(CH_2)_m-C \equiv C-$, and $-(CH_2)_m-C(R_{40})_2-$;

L_2 is a divalent linking group selected from: a bond and



where m is 0 or 1;

R_{BOH} is selected from

1-hydroxycyclopentyl, ~~or~~ and

1-hydroxycyclohexyl, and

R_C is a group selected from

-C(O)NH-CH₂-C(O)OH,

-C(O)NH-CH(Me)-C(O)OH,


-C(O)NH-C(Me)₂-C(O)OH,

-C(O)NMe-CH₂-C(O)OH,

-C(O)NMe-CH(Me)-C(O)OH, ~~or~~ and

-C(O)NMe-C(Me)₂-C(O)OH;

4. (currently amended) A compound represented by formula (III) or a pharmaceutically acceptable salt thereof:



wherein;

R and R' are independently methyl or ethyl;

R1 and R2 are independently methyl or ethyl;

R_{BOH} is selected from

3-methyl-3-hydroxypentyl,

3-methyl-3-hydroxypentenyl,

3-methyl-3-hydroxypentynyl,

3-ethyl-3-hydroxypentyl,

3-ethyl-3-hydroxypentenyl,

3-ethyl-3-hydroxypentynyl,

3-propyl-3-hydroxypentyl,

3-propyl-3-hydroxypentenyl,

3-propyl-3-hydroxypentynyl,


3-ethyl-3-hydroxy-4-methylpentyl,
 3-ethyl-3-hydroxy-4-methylpentenyl,
 3-ethyl-3-hydroxy-4-methylpentynyl, ~~and~~
 1-hydroxy-2-methyl-1-(methylethyl)propyl;
 and

R_C is a group selected from


-C(O)NH-CH₂-C(O)OH,
 -C(O)NH-CH(Me)-C(O)OH,
 -C(O)NH-C(Me)₂-C(O)OH,
 -C(O)NH-C(Me)₂-C(O)OH,
 -C(O)NMe-CH₂-C(O)OH,
 -C(O)NMe-CH(Me)-C(O)OH,
 -C(O)NMe-C(Me)₂-C(O)OH, and
 C(O)-NH-5-tetrazolyl.

5. (previously presented) A compound represented by formula (AA-1) to (AA-33)
 or a pharmaceutically acceptable salt thereof:


AA-1)




AA-2)




AA-3)




AA-4)




AA-5)




AA-6)




AA-7)




AA-8)




AA-9)




AA-10)




AA-11)




AA-12)




AA-13)




AA-14)




AA-15)




AA-16)




AA-17)




AA-18)




AA-19)




AA-20)




AA-21)




AA-22)




AA-23)




AA-24)




AA-25)




AA-26)




AA-27)




AA-28)




AA-29)




AA-30)



AA-31)




AA-32)




or

AA-33)




6. (previously presented) A compound represented by formula (BB-1) to (BB-33) or a pharmaceutically acceptable salt thereof:


BB-1)




BB-2)




BB-3)




BB-4)




BB-5)




BB-6)




BB-7)




BB-8)




BB-9)




BB-10)




BB-11)




BB-12)




BB-13)




BB-14)




BB-15)




BB-16)




BB-17)




BB-18)




BB-19)




BB-20)




BB-21)




BB-22)




BB-23)




BB-24)




BB-25)




BB-26)




BB-27)



BB-28)




BB-29)




,

BB-30)




,

BB-31)




,

BB-32)




, or

BB-33)




7. (previously presented) A compound represented by formula (CC-1) to (CC-44) or a pharmaceutically acceptable salt thereof:


CC-1)




CC-2)




CC-3)




CC-4)




CC-5)




CC-6)




CC-7)




CC-8)




CC-9)




CC-10)




CC-11)




CC-12)




CC-13)




CC-14)




CC-15)




CC-16)




CC-17)




CC-18)




CC-19)




CC-20)




CC-21)




CC-22)




CC-23)




CC-24)




CC-25)




CC-26)




CC-27)




CC-28)




CC-29)




CC-30)




CC-31)




CC-32)




CC-33)




CC-34)




CC-35)




CC-36)




CC-37)




CC-38)




CC-39)




CC-40)




CC-41)



CC-42)




CC-43)




, or

CC-44)




8. (previously presented) The compound according to claim 1 represented by the formula:




or a pharmaceutically acceptable salt thereof.

9. (previously presented) A compound represented by the formula:



or a pharmaceutically acceptable salt thereof.

10. (currently amended) The prodrug derivative of the A compound represented by a formula below or a pharmaceutically acceptable salt thereof:



wherein:


R and R' are independently C₁-C₅ alkyl;

R1 and R2 are independently hydrogen or C₁-C₅ alkyl;

L₁ is a divalent linking group selected from: a bond, $\text{---}(\text{CH}_2)_m\text{---}\overset{\text{O}}{\parallel}\text{C}\text{---}$,
 $\text{---}(\text{CH}_2)_m\text{---O}\text{---}$, $\text{---}(\text{CH}_2)_m\text{---CH=CH}\text{---}$,

$\text{---}(\text{CH}_2)_m\text{---}\overset{\text{R40}}{\underset{\text{R40}}{\text{C}}}\text{---}$,
 $\text{---}(\text{CH}_2)_m\text{---C}\equiv\text{C}\text{---}$, and

L₂ is a divalent linking group selected from: a bond and



where m is 0, 1 or 2, and each R40 is independently hydrogen, C₁-C₅ alkyl, or C₁-C₅ fluoroalkyl;

RBOH is

3-methyl-3-hydroxypentyl,

3-methyl-3-hydroxypentenyl,

3-methyl-3-hydroxypentynyl,

3-ethyl-3-hydroxypentyl,

3-ethyl-3-hydroxypentenyl,

3-ethyl-3-hydroxypentynyl,

3-ethyl-3-hydroxy-4-methylpentyl,

3-ethyl-3-hydroxy-4-methylpentenyl,

3-ethyl-3-hydroxy-4-methylpentynyl,

3-propyl-3-hydroxypentyl,

3-propyl-3-hydroxypentenyl,

3-propyl-3-hydroxypentynyl,

1-hydroxy-2-methyl-1-(methylcetyl)propyl,

1-hydroxycyclopropyl,

1-hydroxycyclobutyl,

1-hydroxycyclopentyl, or

1-hydroxycyclohexyl;

provided, however, provided that when

R_{BOH} is

3-methyl-3-hydroxypentyl,

3-methyl-3-hydroxypentenyl,

3-methyl-3-hydroxypentynyl,

3-ethyl-3-hydroxypentyl,

3-ethyl-3-hydroxypentenyl,

3-ethyl-3-hydroxypentynyl,

3-ethyl-3-hydroxy-4-methylpentyl,

3-ethyl-3-hydroxy-4-methylpentenyl,

3-ethyl-3-hydroxy-4-methylpentynyl,

3-propyl-3-hydroxypentyl,

3-propyl-3-hydroxypentenyl,

3-propyl-3-hydroxypentynyl, or

1-hydroxy-2-methyl-1-(methylethyl)propyl;

then L₁ and L₂ combine as a bond; and

R_C is

-C(O)NH-CH₂-C(O)OH,

-C(O)NH-CH(Me)-C(O)OH,

-C(O)NH-C(Me)₂-C(O)OH,

-C(O)NMe-CH₂-C(O)OH,

-C(O)NMe-CH(Me)-C(O)OH,

-C(O)NMe-C(Me)₂-C(O)OH, or

-5-tetrazolyl.

~~according to claim 1~~ wherein a carboxylic acid group of R_C is esterified to a methyl ester; ethyl ester; N,N-diethylglycolamido ester; or morpholinylethyl ester group.

11. (previously presented) The salt derivative of the compound of claim 1 wherein the salt is sodium or potassium.

12. (previously presented) A pharmaceutical formulation comprising the compound of claim 1 together with a pharmaceutically acceptable carrier or diluent.

13-16. (canceled)

17. (withdrawn, currently amended) A method of treating a mammal to prevent or alleviate the pathological effects of ~~Acne, Actinic keratosis, Alopecia, Alzheimer's disease, Bone maintenance in zero gravity, Bone fracture healing, Breast cancer, Chemoprevention of Cancer, Crohn's disease, Colon cancer, Type I diabetes, Host graft rejection, Hypercalcemia, Type II diabetes, Leukemia, Multiple sclerosis, Myelodysplastic syndrome, Insufficient sebum secretion, Osteomalacia, Osteoporosis or, Insufficient dermal firmness, Insufficient dermal hydration, Psoriatic arthritis, Prostate cancer, Psoriasis, Renal osteodystrophy, Rheumatoid arthritis, Scleroderma, Skin cancer, Systemic lupus erythematosus, Skin cell damage from Mustard vesicants, Ulcerative colitis, Vitiligo, or Wrinkles~~; wherein the method comprises administering a pharmaceutically effective amount of at least one compound of claim 1.

18. (withdrawn) The method of claim 17 for the treatment of psoriasis.

19. (withdrawn) The method of claim 17 for the treatment of osteoporosis.

20-28. (canceled)